Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir

Inclusion Criteria Patients must have: * Serologically documented HIV infection. * Baseline CD4 count greater than or equal to 50 cells and vRNA greater than or equal to 10,000 copies/ml. * Parental consent for patients under 18. Nelfinavir-Failure Group: * Must have protease inhibitor experience solely with nelfinavir and be considered drug-adherent. * Must be candidate for changing therapy because of virologic failure and be receiving nelfinavir at entry (at least 16 weeks of nelfinavir plus NRTI therapy with at least a 10-fold decline in vRNA due to nelfinavir therapy and a subsequent increase toward the patient's baseline vRNA of at least 10-fold). Control Group: * Must have received any combination of currently licensed nucleoside reverse transcriptase inhibitors for at least 16 weeks. * Must be naive to efavirenz, adefovir dipivoxil, and other NRTI's. Exclusion Criteria Prior Medication: Excluded: Control group: * Prior efavirenz, adefovir dipivoxil, or other non-nucleoside reverse transcriptase inhibitors. Required: Nelfinavir-failure patients: * At least 16 weeks of nelfinavir. Control group: * At least 16 weeks of any combination of currently licensed nucleoside reverse transcriptase inhibitors.